TherapeuticsMD, Inc. SEC filings TXMD
TherapeuticsMD, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 23, 2008. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| POS AM | Filing | Mar 24, 2022 | — |
| S-8 | Employee stock plan registration | Oct 15, 2021 | — |
| S-8 | Employee stock plan registration | Aug 31, 2021 | — |
| S-8 | Employee stock plan registration | Jun 8, 2021 | — |
| S-3ASR | Automatic shelf registration | Mar 4, 2021 | — |
| 424B2 | Prospectus | Feb 16, 2021 | — |
| 424B5 | Prospectus supplement | Feb 10, 2021 | — |
| 424B5 | Prospectus supplement | Nov 27, 2020 | — |
| 424B2 | Prospectus | Nov 12, 2020 | — |
| 424B5 | Prospectus supplement | Nov 9, 2020 | — |
| S-8 | Employee stock plan registration | Aug 7, 2020 | — |
| POS AM | Filing | Feb 24, 2020 | — |
| 424B2 | Prospectus | Oct 25, 2019 | — |
| FWP | Free writing prospectus | Oct 24, 2019 | — |
| FWP | Free writing prospectus | Oct 23, 2019 | — |
| 424B5 | Prospectus supplement | Oct 23, 2019 | — |
| S-8 POS | Post-effective amendment to a s-8 | Jun 21, 2019 | — |
| S-8 | Employee stock plan registration | Jun 21, 2019 | — |
| 424B2 | Prospectus | Aug 2, 2018 | — |
| 424B2 | Prospectus | Aug 2, 2018 | — |
| 424B5 | Prospectus supplement | Jul 31, 2018 | — |
| 424B5 | Prospectus supplement | Jul 31, 2018 | — |
| S-3ASR | Automatic shelf registration | Jul 31, 2018 | — |
| 424B2 | Prospectus | Sep 27, 2017 | — |
| 424B5 | Prospectus supplement | Sep 26, 2017 | — |
| 424B2 | Prospectus | Jan 7, 2016 | — |
| 424B5 | Prospectus supplement | Jan 5, 2016 | — |
| S-3 | Shelf registration | Nov 5, 2015 | — |
| 424B5 | Prospectus supplement | Jul 10, 2015 | — |
| 424B2 | Prospectus | Feb 12, 2015 | — |
| 424B5 | Prospectus supplement | Feb 10, 2015 | — |
| S-3 | Shelf registration | Dec 19, 2014 | — |
| 424B2 | Prospectus | Jul 30, 2014 | — |
| 424B5 | Prospectus supplement | Jul 29, 2014 | — |
| S-3MEF | Form s-3mef | Jul 29, 2014 | — |
| 424B7 | Final prospectus supplement | Mar 21, 2014 | — |
| 424B7 | Preliminary prospectus supplement | Mar 18, 2014 | — |
| S-3 | Shelf registration | Jan 24, 2014 | — |
| 424B3 | Prospectus | Dec 24, 2013 | — |
| POS AM | Post-effective amendment no. 2 | Nov 27, 2013 | — |
| 424B3 | Prospectus | Nov 5, 2013 | — |
| 424B3 | Prospectus | Nov 4, 2013 | — |
| S-8 | Employee stock plan registration | Oct 15, 2013 | — |
| POS AM | Post-effective amendment no.1 to s-1 | Oct 9, 2013 | — |
| 424B5 | Prospectus supplement | Sep 25, 2013 | — |
| 424B3 | Prospectus | Aug 7, 2013 | — |
| 424B3 | Prospectus | May 10, 2013 | — |
| 424B5 | Prospectus supplement | Mar 15, 2013 | — |
| 424B3 | Prospectus | Mar 12, 2013 | — |
| 424B5 | Prospectus supplement | Mar 7, 2013 | — |
| S-3 | Shelf registration | Jan 25, 2013 | — |
| 424B3 | Prospectus | Dec 12, 2012 | — |
| S-1 | Registration statement | Nov 27, 2012 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TXMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 25743
- Former names
- AMHN, Inc. (until Sep 14, 2011); CROFF ENTERPRISES INC (until Sep 4, 2009); CROFF OIL CO (until Apr 1, 1997)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.